Immune Checkpoint Inhibitors Market
完整報告名稱與涵蓋範圍
Immune Checkpoint Inhibitors Market Size, Share & Trends Analysis Report, By Drug Class (PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, LAG-3 Inhibitors, Other & Next-Generation Checkpoint Targets), By Indication (Lung Cancer, Melanoma, Renal Cell Carcinoma, Bladder Cancer, Head & Neck Cancer, Hematologic Malignancies), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
Immune checkpoint inhibitors are antibodies that release the molecular brakes tumours exploit to evade immune attack, most prominently by blocking the PD-1, PD-L1 and CTLA-4 axes, with LAG-3 and other next-generation targets extending the class. This report covers approved and late-stage checkpoint therapies across solid tumours and haematologic malignancies, including monotherapy, checkpoint combinations and regimens pairing checkpoint blockade with chemotherapy, targeted agents or antibody drug conjugates.
Expansion is propelled by the migration of checkpoint therapy from metastatic disease into earlier settings, where neoadjuvant and adjuvant approvals in lung, melanoma and urothelial cancers multiply eligible patient populations and lengthen treatment durations. Combination science is the second engine, as bispecific antibodies targeting PD-1 alongside VEGF or other pathways challenge established monotherapy standards and reset licensing valuations. Structural forces include subcutaneous reformulations designed to defend franchises ahead of biosimilar entry as early patents lapse, biomarker refinement around PD-L1 expression, tumour mutational burden and microsatellite instability to focus use on likely responders, and pricing scrutiny from health technology assessment bodies confronting broad eligible populations.
North America generates the largest revenues on early approvals and premium pricing, Europe follows under HTA-managed access, and Asia Pacific is the fastest-expanding arena, propelled by China-developed PD-1 antibodies priced for domestic reimbursement and increasingly licensed westward. The competitive environment is concentrated among a few global franchises, with an aggressive challenger tier of Chinese developers.
The InsightAce study provides US$ revenue forecasts across all drug class, indication, distribution channel and regional segments for 2026-2035, together with trend analysis, competitive landscape assessment and company profiles.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Immune Checkpoint Inhibitors Market Snapshot
Chapter 4. Global Immune Checkpoint Inhibitors Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis
5.1. Drug Class & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Drug Class:
5.2.1. PD-1 Inhibitors
5.2.2. PD-L1 Inhibitors
5.2.3. CTLA-4 Inhibitors
5.2.4. LAG-3 Inhibitors
5.2.5. Other & Next-Generation Checkpoint Targets
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Lung Cancer
6.2.2. Melanoma
6.2.3. Renal Cell Carcinoma
6.2.4. Bladder Cancer
6.2.5. Head & Neck Cancer
6.2.6. Hematologic Malignancies
6.2.7. Other Solid Tumors
Chapter 7. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis
7.1. Distribution Channel & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
7.2.1. Hospital Pharmacies
7.2.2. Specialty Pharmacies
7.2.3. Retail & Online Pharmacies
Chapter 8. Immune Checkpoint Inhibitors Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. Merck & Co. Inc.
10.2. Bristol Myers Squibb
10.3. F. Hoffmann-La Roche Ltd.
10.4. AstraZeneca plc
10.5. Regeneron Pharmaceuticals
10.6. Sanofi
10.7. GSK plc
10.8. Pfizer Inc.
10.9. Merck KGaA
10.10. BeOne Medicines (BeiGene)
10.11. Innovent Biologics
10.12. Junshi Biosciences
10.13. Akeso Inc.
10.14. Agenus Inc.
圖表清單 List of Tables & Figures
Table 1. Global Immune Checkpoint Inhibitors Revenue Forecast by Drug Class, 2026-2035 (US$ Mn)
Figure 1. Mechanism Overview of PD-1, PD-L1, CTLA-4 and LAG-3 Blockade
Table 2. Global Immune Checkpoint Inhibitors Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global Immune Checkpoint Inhibitors Share by Drug Class, 2026 & 2035
Table 3. Global Immune Checkpoint Inhibitors Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 3. Approved Checkpoint Inhibitor Indications by Line of Therapy and Setting
Table 4. North America Immune Checkpoint Inhibitors Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Late-Stage Pipeline of Next-Generation and Bispecific Checkpoint Candidates
Table 5. Europe Immune Checkpoint Inhibitors Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Immune Checkpoint Inhibitors Growth Opportunity Analysis
Table 6. Asia Pacific Immune Checkpoint Inhibitors Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Patent Expiry and Subcutaneous Reformulation Timeline for Leading Franchises
Table 7. Key Licensing Deals for China-Developed Checkpoint Antibodies
Figure 7. Competitive Positioning of Key Immune Checkpoint Inhibitor Developers
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們